risperidone has been researched along with Erectile Dysfunction in 13 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Erectile Dysfunction: The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a 6-week open-label trial, sildenafil was administered to 12 male schizophrenia (DSM-IV) patients, treated with risperidone and reporting erectile dysfunction." | 9.11 | An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. ( Aviv, A; Shelef, A; Weizman, A, 2004) |
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 9.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "A 31-year-old patient suffering from schizophrenic psychosis was treated with risperidone, and developed priapism which required surgical intervention and resulted in long-term erectile dysfunction." | 7.74 | Risperidone-induced priapism. ( Makesar, D; Thome, J, 2007) |
| "In a 6-week open-label trial, sildenafil was administered to 12 male schizophrenia (DSM-IV) patients, treated with risperidone and reporting erectile dysfunction." | 5.11 | An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. ( Aviv, A; Shelef, A; Weizman, A, 2004) |
| "Treatment with risperidone is associated with prolactin (PRL) elevation, and PRL elevations are associated with erectile dysfunction (ED)." | 5.11 | Prolactin levels and erectile function in patients treated with risperidone. ( Bartztokis, G; Cargile, C; Spollen, JJ; Wooten, RG, 2004) |
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 5.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "A computerized search, using the MEDLINE database (1966-summer 2000), located cases of priapism associated with most conventional antipsychotics as well as with clozapine, risperidone, and olanzapine." | 4.81 | Priapism associated with conventional and atypical antipsychotic medications: a review. ( Compton, MT; Miller, AH, 2001) |
| " Peak prolactin levels/any hyperprolactinemia/triple-upper-limit-of-normal-prolactin level were highest with risperidone (median = 56." | 4.31 | Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study. ( Carlson, HE; Correll, CU; Kazimi, MM; Koch, MT, 2023) |
| "A 31-year-old patient suffering from schizophrenic psychosis was treated with risperidone, and developed priapism which required surgical intervention and resulted in long-term erectile dysfunction." | 3.74 | Risperidone-induced priapism. ( Makesar, D; Thome, J, 2007) |
| "The primary objective of the present study was to examine the relationship between sexual dysfunction, subjective well-being and prolactin levels in patients with schizophrenia treated either with risperidone or quetiapine." | 3.74 | Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. ( Albrecht, C; Bliesener, N; Cooper-Mahkorn, D; Creutz, C; Cvetanovska, G; Hornung, WP; Klingmüller, D; Kühn, KU; Lemke, MR; Maier, W; Schubert, M; Sträter, B; Westheide, J, 2008) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| "The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents." | 1.31 | Sexual side effects of novel antipsychotic medications. ( Marder, SR; Pierre, JM; Saunders, CS; Wirshing, DA; Wirshing, WC, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, MT | 1 |
| Carlson, HE | 1 |
| Kazimi, MM | 1 |
| Correll, CU | 1 |
| Meyer, JM | 1 |
| Ishitobi, M | 1 |
| Kosaka, H | 1 |
| Shukunami, K | 1 |
| Murata, T | 1 |
| Wada, Y | 1 |
| Scahill, L | 1 |
| Leckman, JF | 1 |
| Schultz, RT | 1 |
| Katsovich, L | 1 |
| Peterson, BS | 1 |
| Aviv, A | 1 |
| Shelef, A | 1 |
| Weizman, A | 1 |
| Spollen, JJ | 1 |
| Wooten, RG | 1 |
| Cargile, C | 1 |
| Bartztokis, G | 1 |
| Howes, OD | 1 |
| Smith, S | 1 |
| Aitchison, KJ | 1 |
| Makesar, D | 1 |
| Thome, J | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Westheide, J | 1 |
| Cvetanovska, G | 1 |
| Albrecht, C | 1 |
| Bliesener, N | 1 |
| Cooper-Mahkorn, D | 1 |
| Creutz, C | 1 |
| Hornung, WP | 1 |
| Klingmüller, D | 1 |
| Lemke, MR | 1 |
| Maier, W | 1 |
| Schubert, M | 1 |
| Sträter, B | 1 |
| Kühn, KU | 1 |
| Shiwach, RS | 1 |
| Carmody, TJ | 1 |
| Compton, MT | 1 |
| Miller, AH | 1 |
| Wirshing, DA | 1 |
| Pierre, JM | 1 |
| Marder, SR | 1 |
| Saunders, CS | 1 |
| Wirshing, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
1 review available for risperidone and Erectile Dysfunction
| Article | Year |
|---|---|
Priapism associated with conventional and atypical antipsychotic medications: a review.
Topics: Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Clozapine; Erectile Dysfunction; Female; Fo | 2001 |
3 trials available for risperidone and Erectile Dysfunction
| Article | Year |
|---|---|
A placebo-controlled trial of risperidone in Tourette syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Child; Diagnostic Techniques, Neurological; Do | 2003 |
An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Erectile Dysfunction; | 2004 |
Prolactin levels and erectile function in patients treated with risperidone.
Topics: Adolescent; Adult; Affect; Aged; Antipsychotic Agents; Circadian Rhythm; Erectile Dysfunction; Human | 2004 |
9 other studies available for risperidone and Erectile Dysfunction
| Article | Year |
|---|---|
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Erectile Dysfunctio | 2023 |
Sexual dysfunction in patients treated with atypical antipsychotics.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Erectile Dysfunction; Female; Humans; Libido | 2008 |
Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia.
Topics: Adult; Benzothiazoles; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hyperprolactinemia; | 2011 |
Comments on "Prolactin levels and erectile function in patients treated with risperidone" (J Clin Psychopharmacol 2004;24:161-166).
Topics: Antipsychotic Agents; Erectile Dysfunction; Humans; Male; Prolactin; Risperidone; Schizophrenia | 2005 |
Risperidone-induced priapism.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Overdose; Erect | 2007 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Topics: Adult; Antipsychotic Agents; Arousal; Dibenzothiazepines; Erectile Dysfunction; Female; Humans; Libi | 2008 |
Prolactogenic effects of risperidone in male patients--a preliminary study.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedul | 1998 |
Sexual side effects of novel antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Clozapine; Erectile Dysfunction; Fluphenazine; Haloperidol; Humans; Mal | 2002 |